First Digital Health Osteoarthritis Wearable Glove System Starts Pre-launch Pilot Trial Series & Medical Tests

MADRID, Sept. 30, 2019 /PRNewswire/ — QUANTIC NANOTECH, a product division of Spanish DEMAC S.A. group who presented the first home wearable osteoarthritis treatment glove system “QNANO GLOVE” during the last CES 2019 Edition in Las Vegas, announced today the opening of free treatment sign-up registration for a new medical pre-launch pilot trial series for patients in selected hospitals in Madrid. Due to high demand, this new period is open for any user during a limited period until October 15th, 2019 (HIPAA certified secure server in AWS cloud).

Dr. Luis F. Villa, M.D., Rheumatology consultant at University Hospital Puerta de Hierro Majadahonda in Madrid said: 

‘This device attracted our attention because it allows home application in the affected hand of different therapies of evidence-based proven clinical efficacy, during rest or at night’.

And also declared:

“The treatment of hand osteoarthritis is cumbersome and resource consuming, relying on physical assisted therapy and topical and oral medications. We are interested in the results of the pilot studies, since a home-based device for multimodal physical therapy could make it easier and cheaper for the treatment of patients with this frequent condition’.

Quantic Nanotech therapeutic all-in-one glove integrates revolutionary technologies such as shape memory alloys (SMA) and state-of-the-art materials for appliance of dry heat therapy, vibration, massage as well as stretching and extension of the fingers both active and passively. It also allows the administration of topical medications such as non-steroidal anti-inflammatory drugs (NSAID), liniments and neuromodulators.

First conclusion papers of clinical studies in patients with hand osteoarthritis are planned to be reported within Q4 2019 and Q1 2020.

The therapeutic Quantic Glove is simple and compact. It has been designed for use at home, controlled by smartphones or internet and it also allows remote control by health professionals.

The product has been awarded internationally at various shows like InPEX Pittsburgh, etc, and recently it has also won a new 2019 Technology Innovator Award in August 2019 from AI Global Media, UK, 2019 CV-MAGAZINE.

QUANTIC NANOTECH is closing Round A capital raise with aim for rapid worldwide implementation of the product under a patent license model system.

Rheumatism & Osteoarthritis is a very common disease and a major cause of sick leave worldwide, with USD$ 304 Billions of total medical and earning losses just in the US alone – approximately equivalent to 1% of US gross domestic GDP (Source: arthritis.org – 2013).

QUANTIC NANOTECH will be attending GITEX Exhibition in DUBAI Oct 6-10th 2019 in FUTURE STARS area.

About DEMAC S.A QNANOTECH.

About HIPAA 

Logo: http://qwertypanda.healthtechnologynet.com/wp-content/uploads/2019/09/QUANTIC_NANOTECH_Logo.jpg  

Video: https://youtu.be/zQXIRVpriJY  

 

 

View original content:http://www.prnewswire.com/news-releases/first-digital-health-osteoarthritis-wearable-glove-system-starts-pre-launch-pilot-trial-series–medical-tests-300927514.html

SOURCE QUANTIC NANOTECH

Staff

Recent Posts

AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.

Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…

2 hours ago

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

16 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

17 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

17 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

18 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

20 hours ago